Viropro, Inc. and Oncobiologics, Inc. have signed a biosimilar collaboration agreement, under which Viropro will have the rights to manufacture six monoclonal antibody products being developed by Oncobiologics for commercialization in more than 70 emerging markets (excluding China). Viropro will have commercialization rights to the six biosimilars for Malaysia. In addition, the companies will co-manage Viropro’s Alpha Biologics biomanufacturing subsidiary in Penang, Malaysia.    The biosim...